Qualigen Therapeutics (NASDAQ:QLGN) Issues Earnings Results

Qualigen Therapeutics (NASDAQ:QLGN) posted its quarterly earnings data on Friday. The company reported ($4.68) EPS for the quarter, Zacks reports.

Qualigen Therapeutics Stock Up 7.9%

Shares of Qualigen Therapeutics stock traded up $0.20 during trading on Friday, hitting $2.73. 674,531 shares of the company were exchanged, compared to its average volume of 1,034,586. The stock has a market capitalization of $4.63 million, a price-to-earnings ratio of -0.36 and a beta of 0.24. Qualigen Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $8.81. The firm has a 50 day moving average price of $3.49 and a 200 day moving average price of $3.21.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on QLGN shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Qualigen Therapeutics in a report on Wednesday, October 8th. Wall Street Zen upgraded Qualigen Therapeutics to a “sell” rating in a report on Saturday, October 11th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Qualigen Therapeutics presently has an average rating of “Sell”.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.